BACKGROUND: Although portal vein embolization (PVE) has been applied for surgical resection of colorectal liver metastases (CLM), the clinical usefulness of liver surgery following PVE for CLM remains unknown. METHODS: A total of 115 patients were evaluated retrospectively. Among them, 49 underwent one-stage hepatectomy following PVE (PVE group). The remaining 66 patients underwent at least hemihepatectomy without PVE (non-PVE group). This analysis compared the short- and long-term outcomes between the PVE and non-PVE groups. RESULTS: There were no deaths in either group. Using the Clavien-Dindo classification, the rates of postoperative morbidity ≥ grade 1 were 34.7% in the PVE group and 25.0% in the non-PVE group (p = 0.26). The 3-year overall survival rates were 54.6 and 64.5% in the PVE and non-PVE groups, respectively (p = 0.89). The multivariate analysis the variable performance/nonperformance of PVE was not detected as an independent predictor of poor survival. CONCLUSIONS: Our one-stage hepatectomy policy of using PVE provides acceptable morbidity and favorable long-term outcomes.
BACKGROUND: Although portal vein embolization (PVE) has been applied for surgical resection of colorectal liver metastases (CLM), the clinical usefulness of liver surgery following PVE for CLM remains unknown. METHODS: A total of 115 patients were evaluated retrospectively. Among them, 49 underwent one-stage hepatectomy following PVE (PVE group). The remaining 66 patients underwent at least hemihepatectomy without PVE (non-PVE group). This analysis compared the short- and long-term outcomes between the PVE and non-PVE groups. RESULTS: There were no deaths in either group. Using the Clavien-Dindo classification, the rates of postoperative morbidity ≥ grade 1 were 34.7% in the PVE group and 25.0% in the non-PVE group (p = 0.26). The 3-year overall survival rates were 54.6 and 64.5% in the PVE and non-PVE groups, respectively (p = 0.89). The multivariate analysis the variable performance/nonperformance of PVE was not detected as an independent predictor of poor survival. CONCLUSIONS: Our one-stage hepatectomy policy of using PVE provides acceptable morbidity and favorable long-term outcomes.
Authors: N Kokudo; K Tada; M Seki; H Ohta; K Azekura; M Ueno; K Ohta; T Yamaguchi; T Matsubara; T Takahashi; T Nakajima; T Muto; T Ikari; A Yanagisawa; Y Kato Journal: Hepatology Date: 2001-08 Impact factor: 17.425
Authors: D A Wicherts; R J de Haas; P Andreani; D Sotirov; C Salloum; D Castaing; R Adam; D Azoulay Journal: Br J Surg Date: 2010-02 Impact factor: 6.939
Authors: Yoji Kishi; Eddie K Abdalla; Yun Shin Chun; Daria Zorzi; David C Madoff; Michael J Wallace; Steven A Curley; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: Anne M Covey; Karen T Brown; William R Jarnagin; Lynn A Brody; Lawrence Schwartz; Scott Tuorto; Constantinos T Sofocleous; Michael D'Angelica; George I Getrajdman; Ronald DeMatteo; Nancy E Kemeny; Yuman Fong Journal: Ann Surg Date: 2008-03 Impact factor: 12.969
Authors: Sven A Lang; Martin Loss; Volker Benseler; Gabriel Glockzin; Hans J Schlitt Journal: Langenbecks Arch Surg Date: 2015-02-18 Impact factor: 3.445
Authors: Katharina Joechle; Christian Moser; Petra Ruemmele; Katharina M Schmidt; Jens M Werner; Edward K Geissler; Hans J Schlitt; Sven A Lang Journal: World J Surg Oncol Date: 2017-03-07 Impact factor: 2.754